CytomX Therapeutics (NASDAQ:CTMX) Shares Down 4.2% Following Weak Earnings

CytomX Therapeutics, Inc. (NASDAQ:CTMX) shares traded down 4.2% during trading on Tuesday following a dissappointing earnings announcement. The company traded as low as $6.42 and last traded at $6.4660. 3,381,211 shares traded hands during mid-day trading, a decline of 38% from the average session volume of 5,457,485 shares. The stock had previously closed at $6.75.

The biotechnology company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.14). CytomX Therapeutics had a return on equity of 44.49% and a net margin of 24.66%.The business had revenue of $0.66 million during the quarter, compared to the consensus estimate of $7.33 million.

CytomX Therapeutics News Summary

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Strong Phase 1 data — Varsetatug (Varseta‑M) showed confirmed response rates of 32% (10 mg/kg Q3W) and 20% (8.6 mg/kg Q3W) with estimated PFS ~7.1 months at the higher dose; company said FDA interactions are targeted mid‑year to align on a potential registrational trial. This clinical readout is the primary catalyst for the stock rally. GlobeNewswire: Varsetatug data
• Positive Sentiment: Multiple analyst upgrades and price‑target raises — JPMorgan moved CTMX to overweight with a $12 PT, HC Wainwright raised its PT to $17 (buy), and Wedbush lifted its PT to $11 (outperform). These upward revisions amplify investor interest after the clinical update. Benzinga: Analyst price target changes
• Positive Sentiment: Bullish research note — A Seeking Alpha writeup upgraded CTMX to a speculative buy, modeling risk‑adjusted NPV tied to Varseta‑M and estimating a multihandle per‑share valuation based on late‑line mCRC potential. This helps support higher institutional interest. Seeking Alpha: Upgrade/analysis
• Neutral Sentiment: Corporate updates and investor materials — Company released its Q4 results, slide deck and held an earnings call with management commentary and clinical program timelines that investors can review for details. CTMX slide deck / press release
• Negative Sentiment: Planned $250M equity offering — CytomX commenced an underwritten public offering of $250 million in common stock (and pre‑funded warrants for certain investors). While proceeds would fund development, the offering poses dilution risk that can weigh on the share price. GlobeNewswire: Offering announcement
• Negative Sentiment: Q4 earnings and revenue miss — CTMX reported a larger-than-expected loss (EPS -$0.22 vs. est. -$0.08) and revenue of $0.66M versus expectations ~ $7.3M, a near‑term fundamental weakness investors should note. Zacks: Q4 results

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on CTMX shares. HC Wainwright boosted their price objective on CytomX Therapeutics from $10.00 to $17.00 and gave the company a “buy” rating in a research note on Monday. Oppenheimer restated an “outperform” rating and issued a $12.00 target price on shares of CytomX Therapeutics in a research note on Monday. Wedbush lifted their target price on CytomX Therapeutics from $6.00 to $11.00 and gave the company an “outperform” rating in a report on Tuesday. Barclays upped their price target on CytomX Therapeutics from $8.00 to $10.00 and gave the company an “overweight” rating in a research report on Wednesday, February 4th. Finally, Cantor Fitzgerald increased their price target on shares of CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. Eight investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, CytomX Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $11.50.

Hedge Funds Weigh In On CytomX Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Squarepoint Ops LLC grew its stake in CytomX Therapeutics by 4.5% in the 4th quarter. Squarepoint Ops LLC now owns 49,897 shares of the biotechnology company’s stock worth $213,000 after buying an additional 2,169 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of CytomX Therapeutics by 83.2% during the 4th quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 3,000 shares during the last quarter. Velan Capital Investment Management LP grew its position in CytomX Therapeutics by 6.7% in the third quarter. Velan Capital Investment Management LP now owns 80,000 shares of the biotechnology company’s stock worth $255,000 after acquiring an additional 5,000 shares in the last quarter. Farther Finance Advisors LLC purchased a new position in CytomX Therapeutics in the third quarter worth $25,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in CytomX Therapeutics in the fourth quarter valued at $35,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Price Performance

The stock has a 50 day moving average of $5.24 and a 200 day moving average of $4.07. The firm has a market cap of $1.10 billion, a P/E ratio of 16.16 and a beta of 2.44.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.